Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Melanoma
Studies from M.A. Perales et al in the area of melanoma described
February 10th, 2009
According to recent research from the United States, "Granulocte-macrophage colony-stimulating factor (GM-CSF) enhances immune response by inducing proliferation, maturation, and migration of dentric cells (DCs) as well as expansion and differentiation of B and T lymphocytes. The potency of DNA vaccines can be enhaced by the addition of DNA encoding cytokines, acting as molecular adjuvants." "We conducted a phase I/II trial of human GM-CSF DNA in conjunction with a multipeptide vaccine (gp 100 and tyrosine) in stage III/IV melanoma patients. Nineteen human leukocyte antigen (HLA)-A*0201(+) patients were treated. Three dose levels were studied: 100, 400, and 800 mu g...
Source: Cancer Weekly (2009-02-10)
|
